Results 201 to 210 of about 29,210 (297)

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

, 2016
Marco Ruella, Saad S. Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nuñez-Cruz, Michael Klichinsky, Omkar U. Kawalekar, Michael C. Milone, Simon F. Lacey, Anthony R. Mato, Stephen J. Schuster, Michael Kalos, Carl H. June, Saar Gill, Mariusz A. Wasik   +18 more
openalex   +1 more source

Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase. [PDF]

J Virol
Niu K, Wang X, Jiang Q, Liu K, Xie S, Song B, Wu W, Li X, Peng C.   +8 more
europepmc   +1 more source

Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017 [PDF]

, 2017
Stefano Molica
openalex   +1 more source

Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study. [PDF]

Front Oncol
Ivanovic J, Otasevic V, Markovic K, Vukovic V, Bibic T, Tomic Vujovic K, Kozarac S, Vladicic Masic J, Milic N, Kulic J, Antic D.   +10 more
europepmc   +1 more source

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

, 2016
Ariela Noy, Sven de Vos, Catherine Thiéblemont, Peter Martin, Christopher R. Flowers, Franck Morschhauser, Graham P. Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen D. Smith, Alina Smith, Brian Munneke, Isaiah W. Dimery, Darrin M. Beaupre, Robert W. Chen   +15 more
openalex   +1 more source

PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH TREATMENT‐NAÏVE FOLLICULAR LYMPHOMA (PERSPECTIVE) [PDF]

, 2017
S. Rule, Ian W. Flinn, Nathan Fowler, R. Chen, Long Kwei, Darrin M. Beaupre, Alvina D. Chu, Leo I. Gordon   +7 more
openalex   +1 more source

Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study. [PDF]

Biomedicines
Font J, Hodzic A, Da-Silva A, Delapierre B, Damaj G, Neusy A, Plane AF, Legallois D, Milliez P, Dolladille C, Vernon M, Burton S, Vigneron N, Denoyelle C, Alexandre J.   +14 more
europepmc   +1 more source

IBRUTINIB FOR RELAPSED / REFRACTORY CLL: AN UPDATE OF THE UK AND IRELAND ANALYSIS OF OUTCOMES IN 315 PATIENTS [PDF]

, 2017
George Follows, U.K. CLL Forum
openalex   +1 more source

Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE. [PDF]

Ann Hematol
Mishima Y, Hashimoto D, Ichii M, Fukuhara N, Uchida T, Kato K, Omi A, Koroki Y, Shiga K, Maruyama D.   +9 more
europepmc   +1 more source

IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL [PDF]

, 2017
Paula Cramer, Fatih Demırkan, Graeme Fraser, Alexander Pristupa, Nancy L. Bartlett, M.S. Dilhuydy, Javier Loscertales, Abraham Avigdor, Simon Rule, Olga Samoilova, André Goy, Siddhartha Ganguly, Italo Poggesi, Silvia Maria Lavezzi, Giuseppe De Nicolao, Jan de Jong, Martine Neyens, Mariya Salman, Angela Howes, Michelle Mahler   +19 more
openalex   +1 more source